This Week's Biotech IPOs

( - The IPO activity in the U.S. pharma/biotech sector has been somewhat tepid so far this month, with only 1 company having made its market debut on the NASDAQ, i.e., Vaccinex Inc. ( VCNX ) on August 9, at a price of $12 per share.

A new week has just begun, and it's that time to take a look at the U.S. biotech IPO calendar of this week.

Aridis Pharmaceuticals Inc.

Aridis Pharma is a late-stage biopharmaceutical company developing targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat infectious diseases.

The Company is scheduled to list its IPO on the Nasdaq Capital Market, under the symbol "ARDS", on August 14.

Aridis Pharma has offered to sell 2 million shares of its common stock in the offering, and the underwriters have an option for a period of 30 days to purchase up to 300,000 additional shares of common stock.

The initial public offering price is expected to be between $13.00 and $15.00 per share.


The Company has 3 drug candidates in clinical development and 3 in preclinical testing.

-- The lead drug candidate is AR-301 (Salvecin, or tosatoxumab), being developed as an adjunctive immunotherapy in combination with standard of care antibiotics to treat acute pneumonia caused by S. aureus infection. A phase 2a trial with AR-301 has been completed, and a phase III pivotal trial is expected to be initiated in the second half of 2018, with interim data scheduled to be announced in the second half of 2019. AR-301 has been designated an orphan drug in the European Union, and also carries the "Fast Track" tag of the FDA.

-- AR-105, as an adjunctive immunotherapy with standard of care antibiotics to treat acute pneumonia caused by P. aeruginosa infection, under a phase II trial. Interim data from this study is expected to be reported in the first half of 2019. This compound has also been granted Fast-Track designation by the FDA.

-- AR-101 to treat acute pneumonia caused by P. aeruginosa serotype O11, which is expected to enter a phase II/III pivotal trial in the second half of 2019. AR-101 has been granted orphan drug designation in the U.S. and in the EU.

-- AR-401 to treat infection caused by Acinetobacter baumannii, under preclinical testing.

-- AR-201 to treat Respiratory Syncytial Virus infection, under preclinical testing.

-- AR-501 for cystic fibrosis, currently in late preclinical studies. A phase I/IIa trial in healthy adults and cystic fibrosis patients is expected to be initiated in the second half of 2018. The phase I data is anticipated to be reported in 2019 and phase IIa data in 2020.

Read the original article on RTTNews (

For comments and feedback: contact

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of NASDAQ, Inc.